Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure

NCT01961726 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Ischemic Heart Failure

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: 30 mg dose of JVS-100
BIOLOGICAL: 45 mg dose of JVS-100

Sponsor

Juventas Therapeutics, Inc.